Dalian BIO-CHEM Past Earnings Performance
Past criteria checks 2/6
Dalian BIO-CHEM has been growing earnings at an average annual rate of 5.7%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 8.3% per year. Dalian BIO-CHEM's return on equity is 17.7%, and it has net margins of 27%.
Key information
5.7%
Earnings growth rate
6.7%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 8.3% |
| Return on equity | 17.7% |
| Net Margin | 27.0% |
| Next Earnings Update | 25 Apr 2025 |
Recent past performance updates
Recent updates
Shareholders Are Optimistic That Dalian BIO-CHEM (SHSE:603360) Will Multiply In Value
Oct 29
Market Might Still Lack Some Conviction On Dalian BIO-CHEM Company Limited (SHSE:603360) Even After 29% Share Price Boost
Oct 01Here's Why Dalian BIO-CHEM (SHSE:603360) Can Manage Its Debt Responsibly
Sep 26These 4 Measures Indicate That Dalian BIO-CHEM (SHSE:603360) Is Using Debt Reasonably Well
Jun 12Returns on Capital Paint A Bright Future For Dalian BIO-CHEM (SHSE:603360)
Apr 23Dalian BIO-CHEM Company Limited (SHSE:603360) Surges 41% Yet Its Low P/E Is No Reason For Excitement
Apr 01Here's Why Dalian BIO-CHEM (SHSE:603360) Can Manage Its Debt Responsibly
Mar 08Revenue & Expenses Breakdown
How Dalian BIO-CHEM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,110 | 300 | 120 | 46 |
| 30 Jun 24 | 1,076 | 303 | 118 | 42 |
| 31 Mar 24 | 1,146 | 354 | 120 | 41 |
| 31 Dec 23 | 1,066 | 328 | 119 | 39 |
| 30 Sep 23 | 1,104 | 349 | 127 | 35 |
| 30 Jun 23 | 1,169 | 365 | 141 | 34 |
| 31 Mar 23 | 1,220 | 377 | 123 | 40 |
| 31 Dec 22 | 1,257 | 403 | 133 | 47 |
| 30 Sep 22 | 1,318 | 426 | 115 | 57 |
| 30 Jun 22 | 1,192 | 355 | 120 | 57 |
| 31 Mar 22 | 1,082 | 297 | 111 | 49 |
| 31 Dec 21 | 1,006 | 250 | 96 | 40 |
| 30 Sep 21 | 875 | 203 | 85 | 34 |
| 30 Jun 21 | 827 | 217 | 79 | 33 |
| 31 Mar 21 | 768 | 184 | 111 | 33 |
| 31 Dec 20 | 750 | 222 | 108 | 29 |
| 30 Sep 20 | 837 | 251 | 154 | 31 |
| 30 Jun 20 | 920 | 322 | 150 | 31 |
| 31 Mar 20 | 934 | 365 | 121 | 28 |
| 31 Dec 19 | 872 | 307 | 116 | 28 |
| 30 Sep 19 | 727 | 271 | 80 | 26 |
| 30 Jun 19 | 626 | 195 | 77 | 24 |
| 31 Mar 19 | 539 | 150 | 69 | 19 |
| 31 Dec 18 | 528 | 145 | 61 | 19 |
| 30 Sep 18 | 517 | 127 | 52 | 25 |
| 30 Jun 18 | 471 | 109 | 50 | 18 |
| 31 Mar 18 | 440 | 100 | 53 | 17 |
| 31 Dec 17 | 410 | 100 | 55 | 15 |
| 30 Sep 17 | 392 | 107 | 71 | 0 |
| 30 Jun 17 | 393 | 109 | 70 | 0 |
| 31 Mar 17 | 402 | 107 | 70 | 0 |
| 31 Dec 16 | 389 | 98 | 67 | 0 |
| 30 Sep 16 | 365 | 82 | 65 | 0 |
| 31 Dec 15 | 328 | 57 | 55 | 0 |
| 31 Dec 14 | 347 | 64 | 51 | 0 |
| 31 Dec 13 | 291 | 49 | 50 | 0 |
Quality Earnings: 603360 has high quality earnings.
Growing Profit Margin: 603360's current net profit margins (27%) are lower than last year (31.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603360's earnings have grown by 5.7% per year over the past 5 years.
Accelerating Growth: 603360's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603360 had negative earnings growth (-14.3%) over the past year, making it difficult to compare to the Chemicals industry average (-4.7%).
Return on Equity
High ROE: 603360's Return on Equity (17.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 01:27 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dalian BIO-CHEM Company Limited is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andy Liu | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Zhe Wang | Citic Securities Co., Ltd. |
| Wei Liu | Haitong International Research Limited |